

Table S1 Clinicopathological characteristics of patients

	Overall	LCC	LCNEC	SCLC	P-value
	(n = 40)	(n = 10)	(n = 12)	(n = 18)	
Age (years)					0.246
Median, range	63 (46-80)	66 (47-80)	63 (46-77)	61 (47-71)	
Gender [n (%)]					0.192
Female	5 (12.5)	3 (30.0)	1 (8.3)	1 (5.6)	
Male	34 (85.0)	7 (70.0)	10 (83.3)	17 (94.4)	
Unknown	1 (2.5)	0 (0.0)	1 (8.3)	0 (0.0)	
Tumor stage [n (%)]					0.254
Stage I	14 (35.0)	6 (60.0)	1 (8.3)	7 (38.9)	
Stage II	10 (25.0)	2 (20.0)	3 (25.0)	5 (27.8)	
Stage IIIA	12 (30.0)	2 (20.0)	6 (50.0)	4 (2.2)	
Stage IV	1 (2.5)	0 (0.0)	1 (8.3)	0 (0.0)	
Missing	3 (7.5)	0 (0.0)	1 (8.3)	2 (1.1)	
Ki-67 expression (%)					0.1152
Median (range)	70 (20-95)	60 (25-80)	60 (20-95)	80 (50-90)	
Unknown [n, (%)]	2 (5.0)	0 (0.0)	2 (16.7)	0 (0.0)	

LCC: large cell carcinoma; LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer.